IUC24434-82

Abstract Code: IUC24434-82 Real-World Use of Abiraterone and Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Two-Centre UK Experience M.  Ali Hassan 1, J. Kadamala Samuel 2, M. Maffezzoli 3, N. Kolambil Saidalavi 3, R. Arora 3, S. Sandulache 3,...

IUC24433-81

Abstract Code: IUC24433-81 Docetaxel versus olaparib plus abiraterone as first-line treatment in patients with mCRPC: a retrospective single-centre analysis M.  Maffezzoli 1, L. Pedapati 1, M. Hassan 1, S.A. Sandulache 1, J. Samuel 1, F. Di Costanzo 2, G. Neola 3, J....

IUC24421-78

Abstract Code: IUC24421-78 Treatment Timing and Chronobiological Aspects of ADT Resistance in Real-World mCRPC Patients !. Bivolarski 1 (1) Burgas – Bulgaria   Background: Timing may represent an overlooked variable in the treatment of metastatic...

IUC24406-81

Abstract Code: IUC24406-81 ARTA-ATTACK Study: Assessment of Sarcopenia, Frailty, and Neurocognitive Impairment in Patients with Prostate Cancer Treated with Androgen Receptor-Targeted Agents: A Prospective Multicentre Observational Cohort Study G Banna 1, A. Maniam 1,...

IUC24405-80

Abstract Code: IUC24405-80 Retrospective study of Apalutamide/Enzalutamide in Hormone Sensitive Metastatic Prostate Cancer.  S. Okinbaloye 1, G. Olukiran 2, S. Ramamurthy 2, A. Fernandez-Ots 2, C. Arias Quiroz 2, W. Mmeka 2, A. Zarien 2, K. Taft 2, A. Farrer 2, R....

IUC24402-77

Abstract Code: IUC24402-77 Preliminary results of 177Lu-PSMA-617 priming with Enzalutamide in Metastatic Castration-resistant Prostate Cancer: A Single-arm Phase 2 trial (Lu-PRIME) P. Aggarwal 1, S. Satapathy 1, A. Sood 1, S. Goyal 1, G. Prakash 1, B.R. Mittal 1 (1)...
error: Content is protected !!